Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS APRIL ISSUE PUBLISHED
  • APRIL 2021 Issue has been successfully launched on 1 April 2021.

Abstract

DRUG PROFILE OF SOFOSBUVIR - A NUCLEOTIDE ANALOG INHIBITOR OF THE HEPATITIS C VIRUS POLYMERASE

V.R.Ghayathri *, C.Vinodhini, S.Gayatri, K.Chitra

ABSTRACT

Sofosbuvir is the drug of choice for hepatitis C virus (HCV) infection, with a high cure rate. Sofosbuvir is a component of the first all-oral, interferon-free regimen approved by FDA for treatment of chronic hepatitis C. It inhibits the RNA polymerase that the hepatitis C virus uses to replicate its RNA. This review describes the drug profile of sofosbuvir that may recommend major treatment advantages over live benefits.

Keywords: Sofosbuvir, Hepatitis C , GS 331007 , FDA


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More